Female carriers of BRCA1 or BRCA2 pathogenic variants (PV) have increased risks of both breast and ovarian cancer that warrant enhanced surveillance or risk-reducing options.1, 2, 3, 4, 5 Large-scale prospective cohort of primarily high-risk European-ancestry carriers have estimated that the breast cancer cumulative risk to age 70 was 66% (95% CI: 61–72%) for BRCA1 and 61% (95% CI: 55–68%) for BRCA2 and the corresponding ovarian cancer cumulative risks were 41% (95% CI: 33–50%) and 15% (95% CI: 10–23%), respectively.6 The gene discussed is BRCA2; the disease is ovarian carcinoma.